Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:ARCT NASDAQ:HROW NASDAQ:MESO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$95.35-0.7%$76.26$52.50▼$96.56$2.07B0.63630,640 shs414,021 shsARCTArcturus Therapeutics$17.85+6.5%$14.93$8.04▼$25.88$484.71M2.38744,559 shs511,439 shsHROWHarrow$36.99+2.2%$35.29$20.85▼$59.23$1.37B0.33650,285 shs354,912 shsMESOMesoblast$14.39+6.4%$14.08$6.00▼$22.00$1.84B2.26194,742 shs379,111 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals0.00%+1.98%+38.17%+53.89%+51.49%ARCTArcturus Therapeutics0.00%+4.94%+49.00%+39.56%-6.35%HROWHarrow0.00%-5.15%+11.38%+25.01%-5.85%MESOMesoblast0.00%+4.05%-5.89%+22.05%+119.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$95.35-0.7%$76.26$52.50▼$96.56$2.07B0.63630,640 shs414,021 shsARCTArcturus Therapeutics$17.85+6.5%$14.93$8.04▼$25.88$484.71M2.38744,559 shs511,439 shsHROWHarrow$36.99+2.2%$35.29$20.85▼$59.23$1.37B0.33650,285 shs354,912 shsMESOMesoblast$14.39+6.4%$14.08$6.00▼$22.00$1.84B2.26194,742 shs379,111 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals0.00%+1.98%+38.17%+53.89%+51.49%ARCTArcturus Therapeutics0.00%+4.94%+49.00%+39.56%-6.35%HROWHarrow0.00%-5.15%+11.38%+25.01%-5.85%MESOMesoblast0.00%+4.05%-5.89%+22.05%+119.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.10Buy$84.75-11.12% DownsideARCTArcturus Therapeutics 3.00Buy$50.57183.31% UpsideHROWHarrow 3.13Buy$64.6774.82% UpsideMESOMesoblast 3.20Buy$18.0025.09% UpsideCurrent Analyst Ratings BreakdownLatest ARCT, MESO, ANIP, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/22/2025ARCTArcturus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$63.00 ➝ $54.008/21/2025ANIPANI PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $63.008/13/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $64.008/12/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00 ➝ $49.008/12/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $42.008/11/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$65.00 ➝ $77.008/8/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$84.00 ➝ $93.008/8/2025ANIPANI PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M3.37$7.60 per share12.55$19.11 per share4.99ARCTArcturus Therapeutics$152.31M3.18N/AN/A$8.90 per share2.01HROWHarrow$199.61M6.86$0.14 per share270.51$1.95 per share18.97MESOMesoblast$17.20M107.09N/AN/A$4.67 per share3.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$0.77N/A22.65N/A-1.37%25.03%8.00%11/14/2025 (Estimated)ARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)HROWHarrow-$17.48M-$0.25N/A92.48N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)MESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/ALatest ARCT, MESO, ANIP, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 million8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.392.541.96ARCTArcturus TherapeuticsN/A5.905.90HROWHarrow0.780.620.58MESOMesoblast0.111.991.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%ARCTArcturus Therapeutics94.54%HROWHarrow72.76%MESOMesoblast1.43%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%ARCTArcturus Therapeutics15.30%HROWHarrow13.67%MESOMesoblast18.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.70 million18.94 millionOptionableARCTArcturus Therapeutics18027.16 million23.00 millionOptionableHROWHarrow18037.00 million31.94 millionOptionableMESOMesoblast80128.00 million103.93 millionOptionableARCT, MESO, ANIP, and HROW HeadlinesRecent News About These CompaniesMesoblast shares lift following $76m convertible note agreementsSeptember 5 at 12:09 PM | msn.comMesoblast Limited (NASDAQ:MESO) Receives $18.00 Consensus Target Price from AnalystsSeptember 5 at 2:17 AM | americanbankingnews.comHotCopper Trends: Mesoblast raising $50M; Larvotto hits & Alterity HaltSeptember 4 at 2:21 AM | msn.comMesoblast Secures Option for $50 Million Convertible Notes to Bolster GrowthSeptember 4 at 2:21 AM | msn.comMesoblast Enters Into Option To Issue US$50 Million Convertible NotesSeptember 3, 2025 | globenewswire.comMesoblast Limited (NASDAQ:MESO) Given Consensus Rating of "Buy" by BrokeragesSeptember 3, 2025 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Q4 2025 Earnings Call TranscriptSeptember 2, 2025 | insidermonkey.comMesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?August 31, 2025 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Down - What's Next?August 31, 2025 | americanbankingnews.comMesoblast Full Year 2025 Earnings: Misses ExpectationsAugust 29, 2025 | finance.yahoo.comMesoblast Limited 2025 Q4 - Results - Earnings Call PresentationAugust 29, 2025 | seekingalpha.comBanner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®August 28, 2025 | globenewswire.comExamining the Future: Mesoblast's Earnings OutlookAugust 27, 2025 | benzinga.comExamining the Future: Mesoblast's Earnings OutlookAugust 27, 2025 | benzinga.comMesoblast (MESO) to Release Quarterly Earnings on WednesdayAugust 21, 2025 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?August 16, 2025 | marketbeat.comMESO | Mesoblast Ltd. ADR Annual Income Statement | MarketWatchAugust 14, 2025 | marketwatch.comUlcerative Colitis Treatment Landscape Undergoes Rapid Transformation with FDA Approvals and Robust Pipeline | DelveInsightAugust 13, 2025 | theglobeandmail.comMesoblast Limited (NASDAQ:MESO) Given Average Rating of "Buy" by BrokeragesAugust 9, 2025 | marketbeat.comMesoblast (NASDAQ:MESO) Rating Increased to Strong-Buy at Canaccord Genuity GroupAugust 9, 2025 | marketbeat.comXY Capital Ltd Buys New Stake in Mesoblast Limited (NASDAQ:MESO)August 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCT, MESO, ANIP, and HROW Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$95.35 -0.65 (-0.68%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$95.30 -0.05 (-0.05%) As of 09/5/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Arcturus Therapeutics NASDAQ:ARCT$17.85 +1.09 (+6.50%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$17.96 +0.11 (+0.64%) As of 09/5/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Harrow NASDAQ:HROW$36.99 +0.79 (+2.18%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$37.33 +0.34 (+0.91%) As of 09/5/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Mesoblast NASDAQ:MESO$14.39 +0.87 (+6.43%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$14.07 -0.32 (-2.22%) As of 09/5/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
